Cullinan Therapeutics/$CGEM

1D1W1MYTD1Y5YMAX

About Cullinan Therapeutics

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Ticker
$CGEM
Sector
Health
Primary listing
NASDAQ
Employees
109
Headquarters
Cambridge, United States
Website
cullinantherapeutics.com

CGEM Metrics

BasicAdvanced
$1.3B
-
-$3.27
-0.02
-

What the Analysts think about CGEM

Analyst ratings (Buy, Hold, Sell) for Cullinan Therapeutics stock.
Analyst projections of the future price of Cullinan Therapeutics stock.

Bulls say / Bears say

CLN-049 received positive FDA feedback at an End-of-Phase 1 meeting, enabling Cullinan to initiate a potentially registrational Phase 2 study in relapsed/refractory AML in Q3 2026 (GlobeNewswire)
The U.S. FDA accepted an NDA for zipalertinib for previously treated EGFR exon 20 insertion NSCLC, setting a PDUFA action date of February 27, 2027, underscoring near-term regulatory catalysts (GlobeNewswire)
CLN-049 was granted Orphan Drug Designation by the FDA for relapsed/refractory AML in May 2026, highlighting its potential to address a high-unmet-need patient population (GlobeNewswire)
Cullinan reported a net loss of $53.7 million and R&D expenses of $44.4 million in Q2 2026, reflecting high cash burn that could accelerate as multiple late-stage trials commence (GlobeNewswire)
Its early-stage autoimmune programs CLN-978 and velinotamig are still in Phase 1, with pivotal data not expected until late 2026, exposing the stock to binary clinical readout risk (GlobeNewswire)
Chief Scientific Officer Jennifer Michaelson sold 8,000 shares under a Section 16 plan on February 20, 2026, which may signal insider skepticism on current valuation levels (Cullinan Therapeutics SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.

CGEM Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

CGEM Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

CGEM News

AllArticlesVideos

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Business Wire2 days ago

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Benzinga1 month ago

Funds containing CGEM

AllUSDGBPEUR
Funds
Fund name
Fund size
$CGEM weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.07%
iShares Nasdaq US Biotechnology£BTEK
£865M0.07%
Xtrackers S&P 500 Swap£XSPX
£3.1B0.07%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.04%
iShares MSCI World Small Cap$WSML
$9B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.